Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The Bcl2/Shp/Fgf15/lncRNA H19 molecular circuit: a key gatekeeper of bile acid homeostasis

ABSTRACT: Analysis of hepatic gene expression in mice transiently overexpressing Bcl2

ORGANISM(S): Mus musculus

PROVIDER: GSE67972 | GEO | 2017/02/09

SECONDARY ACCESSION(S): PRJNA281392

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Bcl2 is a critical regulator of bile acid homeostasis by dictating Shp and lncRNA H19 function.

Project description: Not available

| S-EPMC4738356 | biostudies-literature

Feeding activates FGF15-SHP-TFEB-mediated lipophagy in the gut

Project description: Not available

| S-SCDT-EMBOJ-2021-109997 | biostudies-other

Combinatorial targeting of MYC/BCL2 double-hit lymphoma with mitochondrial complex I and BCL2 inhibitors

Project description:Activation of the MYC oncogene is common in B-cell lymphomas, and frequently associated with compensatory events that dampen Myc-induced apoptosis, such as over-expression of anti-apoptotic Bcl2-family proteins. For example, concurrent translocations of MYC and BCL2 in a subset of Diffuse large B-cell lymphoma (DLBCL) lead to the high-grade “double-hit” lymphoma subtype (DHL), characterized by dismal prognosis in the face of current front-line regimens, thus calling for the pursuit of tailored therapeutic strategies. Here, we show that Myc and Bcl2 modulate the sensitivity of B-cells to IACS-010759, a selective inhibitor of mitochondrial respiratory complex I. Myc activation in non-transformed lymphoid precursors suppressed endogenous Bcl2 and sensitized the cells to IACS-010759-induced apoptosis. Treatment with the Bcl2 inhibitor venetoclax also sensitized to IACS-010759, while overexpression of Bcl-2 was protective. IACS-010759 engaged an ATF4-driven Integrated Stress Response (ISR) with dual anti- and pro-apoptotic effects, the latter mediated by the CHOP transcription factor, which contributed to selective killing of Myc-overexpressing cells. In line with the above data, IACS-010759 and venetoclax synergized in killing human DHL cells, and showed strong combinatorial effects in a pre-clinical setting. In a Bcl2-negative Burkitt’s lymphoma cell line, instead, IACS-010759 synergized with the Mcl-1 inhibitor S63845. Altogether, our data point to the combination of IACS-010759 with distinct Bcl2-family inhibitors for therapeutic reactivation of the intrinsic apoptotic pathway in Myc-associated B-cell lymphomas

2022-03-01 | GSE149073 | GEO

Feeding activates FGF15-SHP-TFEB-mediated lipophagy in the gut

Project description:Lysosome-mediated macroautophagy, including lipophagy, is activated under nutrient deprivation but is repressed after feeding. We show that feeding unexpectedly activates intestinal lipophagy in a manner dependent on both the orphan nuclear receptor, small heterodimer partner (SHP/NR0B2), and the late fed-state gut hormone, fibroblast growth factor-15/19 (FGF15/19). Postprandial intestinal triglycerides (TGs) and apolipoprotein-B48 (ApoB48), the TG-rich chylomicron marker, were elevated in SHP-knockout and FGF15-knockout mice. Genomic analyses in mouse intestine revealed that SHP partners with the key lysosomal activator, transcription factor-EB (TFEB), upregulating autophagy/lipolysis network genes after feeding. In HT29 intestinal cells, FGF19 treatment activated lipophagy in a manner dependent on both SHP and TFEB, reducing TG and ApoB48 levels. Mechanistically, feeding-induced FGF15/19 signaling increases nuclear localization of TFEB and SHP via PKCβ/ζ-mediated phosphorylation, leading to transcriptional induction of Ulk1 and Atgl. Collectively, these results demonstrate that after feeding, FGF15/19-activated SHP and TFEB paradoxically activate gut lipophagy, limiting postprandial TG levels. As excess lipids cause dyslipidemia and obesity, the FGF15/19-SHP-TFEB axis that reduces intestinal TGs via lipophagic activation provides promising therapeutic targets for obesity-associated metabolic disease.

2022-04-22 | GSE197549 | GEO

GCB subtype DLBCL with BCL2 translocation

Project description:GCB subtype DLBCL with BCL2 translocation

| PRJNA744546 | ENA

GCB subtype DLBCL with BCL2 translocation

Project description:RNA-seq data for 6 de novo GCB subtype DLBCL patients with BCL2 translocation

2022-07-01 | GSE179689 | GEO

Circadian control of bile acid synthesis by a KLF15-Fgf15 axis.

Project description: Not available

| S-EPMC4457302 | biostudies-literature

Glucocorticoid transcriptome in S49 lymphoid cells expressing Bcl2

Project description:S49 (Neo) cells die by apoptosis following dexamethasone (dex) treatment whereas S49 cells expressing Bcl2 are resistant to glucocorticoid-induced cell death. Provocatively, mimicking the loss of intracellular potassium using a low dose of a microbial toxin that acts as a potassium ionophore in combination with dex overcame the resistance afforded by Bcl2 and killed the cells. The ability of the microbial toxin to trigger apoptosis of S49 (Bcl2) cells depends critically on the duration of dex treatment, as a 48-hour dex treatment sensitized the cells to die whereas a 24-hour exposure did not. To determine how the glucocorticoid signaling profile differs at these two time points, we performed RNAseq on RNA isolated from S49 (Neo) cells and S49 (Bcl2) cells treated with and without dex for 24 and 48 hours.

2022-12-28 | GSE210375 | GEO

Combinatorial targeting of MYC/BCL2 double-hit lymphoma with mitochondrial complex I and BCL2 inhibitors

Project description:Combinatorial targeting of MYC/BCL2 double-hit lymphoma with mitochondrial complex I and BCL2 inhibitors

| PRJNA627237 | ENA

Genome-wide analysis of t(14;18)-negative/BCL2 expression-negative FL

Project description:A subset of FL in adults are negative for t(14;18) translocation and BCL2 expression The tumor shows low grade cytology and lack both BCL2 expression and t(14;18) translocation. The genetic alterations involved in the pathogenesis of FL without t(14;18)-negative translocation and BCL2 expression are not well known.

2020-11-23 | GSE80103 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data